Register
Login:
Share:
Email Facebook Twitter


ASCENT RESOURCES: Gas flows mean cash flows to develop up to 15 wells


Regulatory News


Notice of Preliminary Results

Wed, 1st Nov 2017 07:00


RNS Number : 1483V
UDG Healthcare Public Limited Co.
01 November 2017
 

 

1 November 2017

UDG Healthcare plc

Notice of Preliminary Results

 

UDG Healthcare plc ("the Group"), a leading international healthcare services provider, will issue its full year results for the year ending 30 September 2017 at 07:00am (GMT) on Tuesday 28 November 2017.

Brendan McAtamney, CEO and Alan Ralph, CFO will be hosting a presentation for analysts and investors at the London Stock Exchange at 08:30am (GMT) to discuss the company's full year results and provide an update on each of the Group's divisions. They will be joined for a Q&A session by other members of the management team including Jez Moulding, Chief Operating Officer of UDG Healthcare and Executive Vice-President of Ashfield and Mike O'Hara, Managing Director of Sharp Packaging Services. 

Analysts and investors wishing to attend are asked to contact Powerscourt on the details below, as all attendees need to be pre-registered. The presentation will also be available via live audio webcast and conference call, the details of which are below.  

Audio webcast:

https://edge.media-server.com/m6/p/ypnmwqt7 

Conference call dial-in details:

UK

+44(0)20-3427-1916

Ireland

+353(0)-1-246-5603

United States of America

+1-646-254-3366

Participant Code

9761269

 

For further information, please contact:

UDG Healthcare plc

Keith Byrne

 

Head of Investor Relations, Strategy & Corporate Communications

 

Tel: +353-1-468-9000

 

 

 

Powerscourt

 

Lisa Kavanagh / Isabelle Saber

 

Tel: +44-207-250-1446

udghealthcare@powerscourt-group.com

 

 

 

About UDG Healthcare plc:

UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering commercial, clinical, communications and packaging services to the healthcare industry, employing over 9,000 people with operations in 24 countries and delivering services in over 50 countries.

UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.

Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across two broad areas of activity: commercial & clinical services, and communications services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.

Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state of the art facilities across the US and Europe. 

Aquilant is a leading provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.

The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.

For more information, please go to: www.udghealthcare.com

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORZMMFGKMNGNZM





Back to Regulatory News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.